Clinical Trials Directory

Trials / Unknown

UnknownNCT05565690

Role of MRS in Brain Lesions

Diagnostic Yield of Preoperative Magnetic Resonance Spectroscopy for Solitary Intra-axial Brain Lesion in Comparison to Histopathology

Status
Unknown
Phase
Study type
Observational
Enrollment
64 (estimated)
Sponsor
Assiut University · Academic / Other
Sex
All
Age
Healthy volunteers

Summary

Aim of the study is evaluation of accuracy of magnetic resonance spectroscopy in differentiation between neoplastic and non neoplastic lesions and determination the type of neoplasm

Detailed description

The annual global age-standardized incidence of primary malignant brain tumors is \~3.7 per 100,000 for males and 2.6 per 100,000 for females . Rates appear to be higher more in developed countries (males, 5.8 and females, 4.1 per 100,000) than in less developed countries (males 3.0 and females 2.1 per 100,000). More than half of all brain tumors are Intraparenchymal . Diagnosis of brain lesions and other focal intracranial lesions based on imaging methods alone is still facing a challenging problem. Accurate diagnosis is fundamentally vital for clinical management in patients with brain tumors. CT and standard MRI are the first line imaging modalities in evaluation of brain lesions; however, it does not always provide more precise details and characterization of the lesions whether it is benign or malignant. Conventional imaging techniques do not provide exact information about vascularity, cellularity and metabolism of the mass lesion . Magnetic Resonance Spectroscopy (MR Spectroscopy) is one of the tools used to determine themolecular structures of compounds or to detect the compound presence. MR Spectroscopy provides metabolic information from living tissues. The major brain metabolites detected are choline, creatine, N-acetyl aspartate (NAA), lactate, myoinositol, glutamine, glutamate, lipids and the amino acids leucine and alanine. Brain lesions show abnormal values of these metabolites as compared to normal tissue.Our study aims to determine the accuracy of MRS in differentiation between neoplastic and non neoplastic lesions and determination the type of neoplasm, Discriminating neoplastic from non-neoplastic brain lesions is extremely necessary since a misdiagnosis can lead to a severe effect on neurosurgery and exposure to toxic chemotherapy or radiotherapy, which may cause damage to brain tissues.

Conditions

Interventions

TypeNameDescription
DEVICEMRSIt is a tool used to determine the molecular structure of compounds or to detect the compound presence , it provides metabolic information from living brain

Timeline

Start date
2022-10-01
Primary completion
2024-10-01
Completion
2024-11-01
First posted
2022-10-04
Last updated
2022-10-04

Source: ClinicalTrials.gov record NCT05565690. Inclusion in this directory is not an endorsement.